SIK2 and ovarian carcinoma: To exclude potential off-target effects of SIK2 inhibitors, we knocked out endogenous SIK2 by CRISPR/Cas9 and established stable ectopic expression of SIK2 in SKOv3 and OVCAR8 ovarian cancer cells.